News

sharewise39m
Is Novo Nordisk Increasing Dosage to Defend Wegovy's Edge in Obesity?
Novo Nordisk NVO announced that it has submitted a regulatory application to the European Medicines Agency (EMA) seeking ...
MetaVia Inc.: MetaVia Doses First Patient in the 48 mg MAD Cohort of Its Phase 1 Clinical Trial Evaluating DA-1726 for the Treatment of Obesity to Further Explore Maximum ...
Top-Line Data Expected in the Fourth Quarter of 2025 CAMBRIDGE, Mass., July 9, 2025 /PRNewswire/ -- MetaVia Inc. (Nasdaq: MTVA), a clinical-stage biotechnology ...
Rhythm Pharmaceuticals, Inc.: Rhythm Pharmaceuticals Announces Oral MC4R Agonist Bivamelagon Achieved Statistically Significant, Clinically Meaningful BMI Reductions in Placebo ...
Bivamelagon achieved BMI reductions in patients with acquired hypothalamic obesity of -9.3% and -7.7% in 600mg and 400mg cohorts, respectively, at 14 weeks -- -- Post-hoc analysis showed BMI reduction ...
Should Obesity be Classified as a Disease?
To improve access to care, many professional organizations have advocated for classifying obesity as a disease. However, the ...
New obesity definition highlights higher mortality risk for US adults
Dror Dicker of Hasharon Hospital has led to a major shift in how obesity is defined in the United States, with around 50 ...
Major change to health guidelines will lead to a surge in obese Americans
More than 100 million Americans who qualify as overweight could see themselves tip into the obese category under newly ...